The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial
The DOI matches its Crossref record.
Abstract
OBJECTIVE: To compare serum concentrations of inflammatory cytokines, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), adiponectin, and tumor necrosis factor alpha (TNFalpha), before and after 3 months treatment with metformin in obese adolescents with insulin resistance (IR). DESIGN AND SUBJECTS: This was a randomized, double-blinded, clinical trial of two groups of obese adolescents with IR, aged 9-18 years: a placebo group (n=14) and a metformin group (n=12) who received 500 mg metformin every 12 h for 3 months. Anthropometric and biochemical (metabolic and inflammatory cytokines) assessments were compared at the beginning and end of treatment. RESULTS: After 3 months of treatment, body mass index (kg/m2) was reduced in both groups: placebo group (32.82 +/- 6.37-32.10 +/- 6.52; p=0.011) and metformin group (33.44 +/- 5.82-32.71 +/- 5.77; p=0.015). Serum fasting insulin concentrations (pmol/L) increased in the placebo group (189.45 +/- 112.64-266.06 +/- 167.79; p=0.01) and showed a slight decrease in the metformin group (256.82 +/- 113.89-229.25 +/- 86.53; p=0.64). Adiponectin concentrations (microg/mL) decreased in the placebo group (13.17 +/- 7.31-5.65 +/- 6.69; p=0.02), while these remained stable in the metformin group (8.57 +/- 3.98-7.86 +/- 6.23; p=0.64). In the metformin group, significant reductions were found in the variances of serum TNFalpha concentrations (p=0.006; Levene test). CONCLUSION: These results suggest that treating obese adolescents with IR using metformin for 3 months is an option for patients without response to traditional lifestyle change because metformin improves inflammatory activity, which is an etiological factor in cardiovascular disease development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Anti-inflammatory effects of metformin irrespective of diabetes status
Cameron, A. R., Morrison, V. L., Levin, D., Mohan, M., Forteath, C., Beall, C., McNeilly, A. D., Balfour, D. J. K., Savinko, T., Wong, A. K. F., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.308445 · Cited by 704
“suppressing markers of inflammation such as high-sensitivity C-reactive protein in prediabetic individuals(42) and TNF-α in IR individuals.(43) NLR has recently been identified as a predictor of all-cause mortality and cardiovascular events,(31) whereas”
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood
Weihrauch-Blüher, S., Schwarz, P., & Klusmann, J.-H. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.001 · Cited by 566
O’Connor, E. A., Evans, C. V., Burda, B. U., Walsh, E. S., Eder, M., & Lozano, P. (2017) · JAMA · doi:10.1001/jama.2017.0332 · Cited by 500
Metadata
- Authors
- Evia-Viscarra, M. L., Rodea-Montero, E. R., Apolinar-Jiménez, E., Muñoz-Noriega, N., García-Morales, L. M., Leaños-Pérez, C., Figueroa-Barrón, M., Sánchez-Fierros, D., & Reyes-García, J. G.
- Venue
- Journal of Pediatric Endocrinology and Metabolism
- Publisher
- Walter de Gruyter GmbH
- Published
- 2012-01-01
- Volume
- 25
- Issue
- 1-2
- Pages
- 41-9
- ISSN
- 0334-018X (ISSN-L)
- 2191-0251
- OpenAlex
- W2085368829
- Cited by
- 62
- References
- 0
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. https://app.cochat.ai/papers/10.1515/jpem-2011-0469
- The paper
- Evia-Viscarra, M. L., Rodea-Montero, E. R., Apolinar-Jiménez, E., Muñoz-Noriega, N., García-Morales, L. M., Leaños-Pérez, C., Figueroa-Barrón, M., Sánchez-Fierros, D., & Reyes-García, J. G. (2012). The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2011-0469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.